Included in the formulation
АТХ:A.05.B.A.06 Ornithine oxoglurate
Pharmacodynamics:Ornithine acts as a catalyst for the enzymes carbamoyl phosphate synthetase and ornithine carbamoyl transferase, and is also the basis for the synthesis of urea. In addition, the drug reduces the level of ammonia in the body due toammonium groups in the synthesis Urea (in the ornithine cycle of Krebs urine formation).
Also, the drug promotes the production of growth hormone and insulin, improves protein metabolism.
Reduces the concentration of ammonia in the blood plasma, helps normalize acid-base state the body and the production of insulin and STG. Improves protein metabolism in diseases requiring parenteral nutrition.
Pharmacokinetics:When administered ornithine aspartate dissociates into its constituent components (ornithine and aspartate), which are absorbed in the small intestine by active transport through the intestinal epithelium.
It is excreted in the urine through a cycle of urea formation.
Indications:Acute and chronic liver disease (hepatitis, cirrhosis, hepatic encephalopathy (latent and expressed) including as part of complex therapy for impaired consciousness (precoma or coma), which are accompanied by hyperammonemia.
Hyperammonemia.
Dynamic study of pituitary function.
As a corrective additive to preparations for parenteral nutrition to patients with protein deficiency.
IV.E40-E46.E46 Protein-energy insufficiency, unspecified
XI.K70-K77.K72 Hepatic failure, not elsewhere classified
IV.E70-E90.E72.2 Disorders of urea cycle exchange
XI.K70-K77.K74 Fibrosis and cirrhosis of the liver
XI.K70-K77.K76.9 Liver disease, unspecified
Contraindications:Severe renal insufficiency (creatinine concentration more than 3 mg per 100 ml).
Hypersensitivity.
Lactation.
Children under 18 years.
Pregnancy and lactation:Category FDA not determined. During pregnancy, the application is only possible under the strict supervision of the doctor, taking into account the benefit / risk relationship for the mother and the fetus.
If it is necessary to use during the lactation period, the question of stopping breastfeeding should be solved.
Dosing and Administration:Inside, intravenously, intramuscularly.
Oral: after eating, 3 grams of granules, previously dissolved in 200 ml of liquid, 2-3 times a day.
Intramuscularly: 2-6 g per day, 1-2 times a day.
Intravenously drip: dose, duration and frequency of infusions, duration of treatment are determined individually, usually - 20 g in day (previously diluted in 500 ml infusion solution, the maximum infusion rate is 5 g per hour or 40 drops per minute); it is possible to increase the dose to 40 g in day.
Intravenously struino 2-4 g 1-2 times a day.
Side effects:Skin reactions.
Nausea.
Vomiting.
Overdose:Symptoms: increased severity of dose-dependent side effects. Treatment: the drug should be discontinued, gastric lavage, activated charcoal, symptomatic treatment.
Interaction:The drugarmaceutically incompatible (RAsterol should not be mixed in one syringe) with vitamin K, benzathine benzylpenicillin, diazepam, meprobamate, phenobarbital, rifampicin, ethionamide.
Special instructions:If nausea or vomiting occurs, the rate of administration should be optimized.
If you use a particular dosage form of ornithine, you must comply with the specific indications.
The course of treatment can be repeated every 2-3 months.
When administering the drug in high doses, the urea concentration in blood plasma and urine should be monitored.
Impact on the ability to drive vehicles and manage mechanisms
The drug may cause a slowing of the speed of psychomotor reactions and a violation of concentration of attention.